Ferrous Ascorbate vs Iron Polymaltose Complex for Iron Deficiency Anemia in Children

calendar
17 Jul, 23

Introduction


The correction of Iron deficiency anemia (IDA) relies either upon the oral or parenteral route. Oral administration of ferrous salts provides inexpensive and effective improvement in the correction of anemia due to its high bioavailability. However, long duration of treatment along with the issues of compliance and gastrointestinal adverse events are the limitations. 


Aim


To compare the therapeutic efficacy of Ferrous ascorbate (FA) and Iron polymaltose complex in Iron deficiency anemia (IDA) in children


Patient Profile


Children (1 to 12 years) with anemia defined as hemoglobin (Hb) less than 10 (g%).

IDA diagnosis based on the Guidelines by the British Society of Gastroenterology included combination of at least two of the following criteria in addition to Hb <10 (g%) at baseline: lower than normal (80–100 fL) mean corpuscular volume (MCV), raised red cell volume distribution (RDW) than the normal range (11–15%) or low serum ferritin levels (<12 ng/ml but not >100 ng/ml)


Method

Study Design

 

Treatment: Both the groups received iron salts (FA or IPC) randomly in a dose of 6 mg/kg elemental iron for 3 months

Follow-up: Day 3, day 7, at the end of 1 month and 3 months

Efficacy Endpoints: Hemoglobin (Hb), Mean corpuscular volume (MCV), Red cell distribution width (RDW), Reticulocyte count

 


Results


Figure: Comparison of endpoints between study groups

  

 
 
 
 

 

 
 
 
 

FA group

 
 
 
 

IPC group

 
 
 
 

p-value

 
 
 
 

Mean increase in Hb, g(%)

 
 
 
 

 

 
 
 
 

 

 
 
 
 

 

 
 
 
 

Day 7

 
 
 
 

1.56

 
 
 
 

0.95

 
 
 
 

0.00

 
 
 
 

1 month

 
 
 
 

3.13

 
 
 
 

2.0

 
 
 
 

0.017

 
 
 
 

3 months

 
 
 
 

4.88

 
 
 
 

3.33

 
 
 
 

0.001

 
 
 
 

Mean increase in MCV, fL

 
 
 
 

 

 
 
 
 

 

 
 
 
 

 

 
 
 
 

Day 7

 
 
 
 

6.71

 
 
 
 

2.91

 
 
 
 

0.011

 
 
 
 

1 month

 
 
 
 

9.80

 
 
 
 

5.35

 
 
 
 

0.004

 
 
 
 

3 months

 
 
 
 

21.29

 
 
 
 

21.11

 
 
 
 

0.078

 
 
 
 

Mean decrease in RDW, (%)

 
 
 
 

 

 
 
 
 

 

 
 
 
 

 

 
 
 
 

Day 7

 
 
 
 

2.24

 
 
 
 

1.31

 
 
 
 

0.098

 
 
 
 

1 month

 
 
 
 

4.23

 
 
 
 

2.67

 
 
 
 

0.005

 
 
 
 

3 months

 
 
 
 

5.74

 
 
 
 

4.04

 
 
 
 

0.006

 
 
 
 

Mean increase in reticulocyte count (%)

 
 
 
 

 

 
 
 
 

 

 
 
 
 

 

 
 
 
 

Day 3

 
 
 
 

0.88

 
 
 
 

0.43

 
 
 
 

0.017

 
 
 
 

Day 7

 
 
 
 

4.00

 
 
 
 

2.19

 
 
 
 

0.001

 

  • Hb increase at 1 mo and 3 mo, MCV increase at day 7 and 1 mo, RDW decrease at 1 and 3 mo and reticulocyte count at day 3 and day 7 were found to be statistically better in FA than IPC. The early improvement in hematological parameters in FA supplemented patients will help in early initiation of replenishment of iron stores. This could be attributed to better absorption of FA. It is resistant to oxidation at alkaline pH, delivers the maximum amount of ferrous iron to the duodenal brush border and at the same time produces minimum gastrointestinal (GI) adverse effects.

  • IPC is generally well tolerated and appears to cause significantly less gastrointestinal disturbance than ferrous salts.


Safety: FA group had minor adverse reactions whereas the IPC group had none


Conclusion

 

  • Both FA and IPC used in treatment of IDA showed a significant statistical improvement in haematological parameters during 3 months of intervention. 

  • Improvement in haematological parameters was better in FA supplemented patients as compared to IPC.

 

Indian J Pediatr. 2019 Dec;86(12):1112-1117

https://doi.org/10.1007/s12098-019-03068-2